The shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) traded with a loss of -1.36 points or -0.9% in the most recent session. The shares last traded at $149.4. As per the trading info, the shares saw $12.83 million in upticks and lost $11.07 million in downticks, resulting in a net money flow of $1.76 million. The up/down ratio for the day was measured at 1.16. For the week, the shares had posted -2.19%.From the block trade data available, the total upticks were valued at $2.46 million and the total downticks were valued at $0 million, thereby putting the up/down ratio at 0. The net money flow for the block transaction was $2.46 million.
Currently the company Insiders own 4.2% of Jazz Pharmaceuticals plc shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.45% . Institutional Investors own 90.03% of Jazz Pharmaceuticals plc shares. During last six month period, the net percent change held by insiders has seen a change of -3.37%. On the companys insider trading activities, The director, of Jazz Pharmaceuticals Plc, Mulligan Seamus had unloaded 27,968 shares at $150.13 per share in a transaction on May 24, 2016. The total value of transaction was $4,198,836. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stock ended Monday session in the red zone in a volatile trading. The stock closed down 2.19 points or 1.45% at $148.57 with 717,657 shares getting traded. Post opening the session at $149.54, the shares hit an intraday low of $148.47 and an intraday high of $152.27 and the price was in this range throughout the day. The company has a market cap of $8,977 million and the number of outstanding shares have been calculated to be 60,421,794 shares. The 52-week high of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is $194.73 and the 52-week low is $108.5.
Many analysts have stated their opinion on the company shares. Goldman Sachs initiates coverage on Jazz Pharmaceuticals plc (NASDAQ:JAZZ) The brokerage firm has issued a Buy rating on the shares. The Analysts at the ratings agency announces the price target to $196 per share. The rating by the firm was issued on June 6, 2016.